Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03660943 · ClinicalTrials.gov registry record · Phase 3

A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain

A Phase 3 study of Osteoarthritis, Knee, sponsored by Centrexion Therapeutics.

Completed
Registry status
Phase 3
Development phase
332
Enrollment target
20
Study locations

NCT03660943: Completed Phase 3 study of Osteoarthritis, Knee, sponsored by Centrexion Therapeutics.

NCT03660943 is a Phase 3 study of Osteoarthritis, Knee that has completed, run by Centrexion Therapeutics. The registered enrollment target is 332 participants, below the 495-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (33% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03660943, a Phase 3 study of Osteoarthritis, Knee, has completed, sponsored by Centrexion Therapeutics.

COMPLETED
Registry status
Phase 3
Development phase
332 participants
Enrollment target
20
Study locations

Study Summary

This is a randomized, double-blind, placebo-controlled, 2-injection, 52-week study to evaluate the efficacy and safety of intra-articular injections of CNTX-4975-05 in subjects with chronic, moderate-to-severe osteoarthritis knee pain.

Primary Outcome

The Western Ontario and McMaster Universities developed the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score to use among patients with knee and/or hip OA. The WOMAC is a validated, multidimensional measure of pain, stiffness, and physical functional disability that is sensitive to the effects of drugs or other interventions. This study used the 11-box NPRS format ranging from 0 (none or no pain/stiffness/difficulty) to 10 (extreme). The WOMAC is a self-administered index

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG CNTX-4975-05

Study Locations (20)

Florida

  • Panamerican Health Center, Inc. - Miami
  • Well Pharma Medical Research, Corp - Miami
  • Quality Research & Medical Center LLC - Miami
  • San Marcus Research Clinic, Inc. - Miami Lakes
  • Journey Research, Inc. - Oldsmar
  • M&M Clinical Trials Sunrise - Sunrise
  • Conquest Research - Winter Park

Arizona

  • Holland Center for Family Health - Glendale
  • GB Family Care - Phoenix
  • Arizona Research Center - Phoenix

California

  • Med Center Medical Clinic - Carmichael
  • TriWest Research Associates - El Cajon
  • Arthritis Care and Research Center, Inc. (ACRC Studies) - Poway

Illinois

  • Healthcare Research Network, LLC - Flossmoor
  • Affinity Clinical Research Institute - Oak Brook

Connecticut

  • Chase Medical Research, LLC - Waterbury

Georgia

  • Better Health Clinical Research, Inc. - Newnan

Louisiana

  • DelRicht Research - New Orleans

Maryland

  • The Center for Rheumatology and Bone Research - Wheaton

Trial Details

FieldValue
Enrollment Target 332 participants
Start Date 2018-09-09
Est. Completion 2020-06-11
Phase Phase 3
Centrexion Therapeutics

12 total trials

What the finished NCT03660943 record still lists

NCT03660943 is an interventional study that assigns participants to a tested intervention. The registered 332 participants enrollment target is mid-sized for trials with a published cap, below the 495-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (33% lower).

The record links to 1 condition, with Osteoarthritis, Knee appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03660943 names 20 study sites across 9 states, led by Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT03660943 about?

NCT03660943 is a clinical study titled "A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain". This is a randomized, double-blind, placebo-controlled, 2-injection, 52-week study to evaluate the efficacy and safety of intra-articular injections of CNTX-4975-05 in subjects with chronic, moderate-to-severe osteoarthritis knee pain.

What is the current status of trial NCT03660943?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 332 participants. The study started on 2018-09-09. Estimated completion is 2020-06-11.

What conditions does trial NCT03660943 study?

This clinical trial studies the following conditions: Osteoarthritis, Knee.

What interventions are being tested in trial NCT03660943?

The interventions under investigation include: Placebo (DRUG), CNTX-4975-05 (DRUG).

Who is sponsoring clinical trial NCT03660943?

This trial is sponsored by Centrexion Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03660943 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis, Knee

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03660943's enrollment target sits among peer trials

332 25th of 112 higher than 88 of 112 other Osteoarthritis, Knee trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Osteoarthritis, Knee trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174121 · 332 participants · Phase 2

    Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

  • NCT02605785 · 332 participants · NA

    A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy

  • NCT04894006 · 332 participants · NA

    Dementia Family Caregiver Study

  • NCT05130606 · 332 participants · NA

    CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03660943, the US trial registry maintained by the National Library of Medicine. NCT03660943 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.